These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1759519)

  • 21. Immunity to measles in the Croatian population.
    Borcić B; Mazuran R; Kaić B
    Eur J Epidemiol; 2003; 18(11):1079-83. PubMed ID: 14620943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The epidemiological efficacy of mass vaccination against measles among the troops].
    Sibilev VI; Shevtsova VA; Tiasto EA
    Voen Med Zh; 1994 Feb; (2):50-1, 80. PubMed ID: 8165796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995-1997.
    Lee MS; Chien LJ; Yueh YY; Lu CF
    Vaccine; 2001 Sep; 19(32):4644-51. PubMed ID: 11535312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effectiveness of measles immunoprophylaxis and the criteria for assessing its possible elimination].
    Sokhin AA; Sliusar' LI; Ignatov SA; Mekhova LS
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Nov; (11):24-30. PubMed ID: 3799112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The immune status of children in foci of measles infection studied by an immunoenzyme method].
    Iuminova NV; Unanov SS; Krasnova VP; Malancheva OA; Kovaleva LG; Liashenko VA
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Aug; (8):35-8. PubMed ID: 2239001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measles antibodies and response to vaccination in children aged less than 14 months: implications for age of vaccination.
    Borràs E; Urbiztondo L; Costa J; Batalla J; Torner N; Plasencia A; Salleras L; Domínguez À;
    Epidemiol Infect; 2012 Sep; 140(9):1599-606. PubMed ID: 22074684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Herd immunity to measles virus in a population of student nurses and medical students following a widespread outbreak of clinical measles in Ibadan, Nigeria.
    Forbi JC; Kfutwah AK; Oyedele OI; Adu FD; Odemuyiwa SO
    West Afr J Med; 2000; 19(4):309-11. PubMed ID: 11391847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Seroresponse to the second measles vaccine dose at school entry in Qassim province, Saudi Arabia.
    Khalil MK; Nadrah HM; Al Yahia OA; ElGhazali G
    East Mediterr Health J; 2011 Mar; 17(3):191-5. PubMed ID: 21735958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Various regularities of measles epidemic process during a period of mass vaccination of children].
    Schwars SA; Bukova VE
    Vopr Virusol; 1976; (4):420-5. PubMed ID: 137586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measles vaccination policy.
    Williams BG; Cutts FT; Dye C
    Epidemiol Infect; 1995 Dec; 115(3):603-21. PubMed ID: 8557092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Measles at the point of being eliminated].
    De Ory F; Peña-Rey I
    Enferm Infecc Microbiol Clin; 2010 Feb; 28(2):73-4. PubMed ID: 20096973
    [No Abstract]   [Full Text] [Related]  

  • 33. Optimal age for vaccination against measles in the State of São Paulo, Brazil, taking into account the mother's serostatus.
    Zanetta RA; Amaku M; Azevedo RS; Zanetta DM; Burattini MN; Massad E
    Vaccine; 2001 Oct; 20(1-2):226-34. PubMed ID: 11567768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humoral and cellular immune response after measles vaccination in Taiwan.
    Huang CL; Yang YH; Wang LC; Lin YT; Tsai YY; Chiang BL
    J Microbiol Immunol Infect; 2005 Jun; 38(3):169-75. PubMed ID: 15986066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reconstruction of measles dynamics in a vaccinated population.
    Wallinga J; Teunis P; Kretzschmar M
    Vaccine; 2003 Jun; 21(19-20):2643-50. PubMed ID: 12744901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The sero-epidemiology of measles in children from Eastern Turkey.
    Altinkaynak S; Ertekin V; Güraksin A; Kiliç A; Yiğit N
    West Indian Med J; 2005 Sep; 54(4):236-7. PubMed ID: 16312189
    [No Abstract]   [Full Text] [Related]  

  • 37. Predicting and comparing long-term measles antibody profiles of different immunization policies.
    Lee MS; Nokes DJ
    Bull World Health Organ; 2001; 79(7):615-24. PubMed ID: 11477964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunological effectiveness of a booster inoculation against measles in children remaining seronegative after vaccination].
    Bolomovskiĭ VM; Gelikman BG; Titova NS; Slavnitskaia IV; Auzinia AV
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Jul; (7):100-6. PubMed ID: 6333122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measles outbreak in Ibadan: clinical, serological and virological identification of affected children in selected hospitals.
    Adu FD; Ikusika A; Omotade O
    J Infect; 1997 Nov; 35(3):241-5. PubMed ID: 9459395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seroconversion after measles vaccination at nine and fifteen months of age.
    Işik N; Uzel N; Gökçay G; Kiliç A; Yilmaz G; Sadikoğlu B; Diri S
    Pediatr Infect Dis J; 2003 Aug; 22(8):691-5. PubMed ID: 12913768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.